Skip to main content
Fig. 5 | Genome Medicine

Fig. 5

From: CEOP/IVE/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with peripheral T cell lymphoma: results from a phase 2, multicenter, randomized, controlled clinical trial

Fig. 5

Gene mutations and treatment response/survival outcomes. a Relation between treatment response (including complete response, partial response, and no response) and gene mutation profile. b–d Kaplan-Meier curves showed progression-free survival (upper panel) and overall survival (lower panel) of PTCL patients, according to the mutation status of CREBBP (b), IDH2 (c), and KMT2D (d)

Back to article page

Genome Medicine

ISSN: 1756-994X

Contact us